NurExone’s exosomes are good at finding damaged tissue. Getting them past the skin’s outer barrier without breaking apart along the way is a separate problem entirely. This week the company partnered with an Israeli device maker that already has an FDA-cleared answer to exactly that problem, the same week its shareholders quietly handed the board the tools it would need to eventually pursue a US exchange listing.
NurExone Partners With NanoPass to Test Exosome Delivery for Eye and Skin
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) announced on September 14 that its Israeli subsidiary has signed a non-binding memorandum of understanding with NanoPass Technologies Ltd. to evaluate combining NanoPass’s MicronJet intradermal delivery platform with NurExone’s exosome formulations for eye and skin applications. NanoPass’s device, already FDA-cleared, uses microscopic, MEMS-fabricated silicon needles to place a formulation precisely within the skin rather than leaving it to sit on the surface, a delivery problem that has limited how well exosome-based products can be applied topically.
Two applications are on the table. For ophthalmology, the companies plan a preclinical study evaluating MicronJet for suprachoroidal delivery of ExoPTEN, NurExone’s lead exosome candidate, into the eye. For dermatology and aesthetics, the collaboration runs through NurExone’s US subsidiary, Exo-Top, targeting a regenerative aesthetics market the companies size at roughly $17.7 billion in 2026, growing to about $28.9 billion by 2030. Under the MOU, each company funds its own activities; there is no committed spending, revenue-sharing arrangement, or exclusivity disclosed at this stage, and it is a memorandum of understanding rather than a definitive commercial agreement.
Shareholders Hand the Board Tools for a Future Nasdaq Listing
At its annual and special meeting held September 15, NurExone shareholders approved a resolution authorizing the board, at its sole discretion, to implement a share consolidation of up to 30 pre-consolidation shares for each post-consolidation share, at any point over the next 36 months, subject to TSXV acceptance. Chairman Yoram Drucker framed the vote as an enabling step tied to the company’s broader capital-markets strategy, including a potential future US exchange listing. The company’s own release is explicit that no final decision has been made to implement the consolidation or to pursue any US listing, and that shareholder approval does not obligate the board to act.
Alongside the AGM results, NurExone disclosed a new investor-relations engagement with Acorn Management Partners, a US-based firm that will work to raise the company’s visibility with US brokers and investment professionals. The arrangement is cash-only, capped at US$180,000 over its 12-month term, with no shares issued as compensation and no Acorn personnel currently holding or intending to acquire NurExone stock, according to the company’s disclosure.
The Core Program Behind the Expansion
NurExone’s lead candidate, ExoPTEN, is a preclinical-stage exosome therapy for acute spinal cord and optic nerve injury that holds Orphan Drug Designation and has generated preclinical data the company says supports its potential in both indications. In its second quarter 2026 financial results, NurExone reported a net loss of US$1.68 million, roughly flat with the prior year, funded in part by private placements completed in June and August 2026. The company is working with contract manufacturer Made Scientific on US GMP-compliant manufacturing tech transfer, targeting initial exosome batches in the first half of 2027, a step management says is intended to support a potential IND submission in that same window.
What to Watch
The NanoPass collaboration has no disclosed timeline for moving from evaluation to a defined product or commercial arrangement; whether it produces usable preclinical data for either the ophthalmic or aesthetic application is the concrete next signal. On the capital-markets side, whether the board actually implements the share consolidation, and whether that leads anywhere near an actual Nasdaq listing application, remain open questions the company itself has declined to commit to. The more fundamental near-term milestone is still ExoPTEN’s path toward an IND submission targeted for the first half of 2027, which depends on the GMP manufacturing tech transfer landing on schedule.
Sources
- BioSpace: NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications, September 14, 2026
- RTTNews: NurExone, NanoPass Enter MOU To Evaluate Exosome Delivery For Eye & Skin Applications, September 14, 2026
- GlobeNewswire: NurExone Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update, September 16, 2026
- BioSpace: NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results, August 31, 2026
Editorial Disclosure
This article is based entirely on publicly available information including company press releases and news coverage. The security discussed is NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90). aktiego.com has not received any compensation from NurExone Biologic, its management, investor relations representatives, or any third party. No staff member or principal of aktiego.com holds a position in this security at the time of publication.
The NanoPass collaboration is a non-binding memorandum of understanding; each party funds its own activities, and there is no disclosed definitive commercial agreement, exclusivity, or committed revenue at this stage. ExoPTEN and any application arising from the NanoPass collaboration are investigational and have not been approved by the FDA, Health Canada, or any other regulatory authority for any indication. NurExone’s share consolidation resolution and any potential US exchange listing are both explicitly undecided as of this writing, per the company’s own disclosure; shareholder approval provides discretionary authority only and does not obligate the board to act, and there is no assurance either initiative will be implemented or completed. The IND submission and manufacturing timelines targeted for the first half of 2027 are company-stated goals, not guarantees, and remain subject to regulatory authorization and completion of required development activities. Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of NurExone’s press releases, per the company’s own standard disclosure.
Small cap and micro-cap stocks listed on the CSE, TSX, TSXV, and Nasdaq are speculative investments carrying significant risk including potential total loss of capital. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER
